← Back to Search

Propranolol for Autism Spectrum Disorder

N/A
Waitlist Available
Led By David Q Beversdorf, MD
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of autism spectrum disorder (ASD), defined in this study by the DSM-V criteria plus Autism Diagnostic Observation Schedule (ADOS) criteria for Autism.
Aged 3-8
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights

Study Summary

This trial is testing whether propranolol combined with behavioral intervention can improve social interaction, language, anxiety, and adaptive behaviors in children with autism.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in General Social Outcome Measure (GSOM)
Change in Social Responsiveness Scale (SRS)
Secondary outcome measures
Change in Aberrant Behavior Checklist (ABC)
Change in Autism Impact Measure (AIM)
Change in Preschool Anxiety Scale (PAS)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Propranolol armExperimental Treatment1 Intervention
Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing > 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing < 15 kg will be excluded for safety reasons.
Group II: Placebo armPlacebo Group1 Intervention
Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Propranolol
2010
Completed Phase 4
~1290

Find a Location

Who is running the clinical trial?

Autism Science FoundationOTHER
4 Previous Clinical Trials
183 Total Patients Enrolled
4 Trials studying Autism Spectrum Disorder
183 Patients Enrolled for Autism Spectrum Disorder
University of Missouri-ColumbiaLead Sponsor
360 Previous Clinical Trials
627,954 Total Patients Enrolled
8 Trials studying Autism Spectrum Disorder
1,874 Patients Enrolled for Autism Spectrum Disorder
David Q Beversdorf, MDPrincipal InvestigatorUniversity of Missouri-Columbia
4 Previous Clinical Trials
103 Total Patients Enrolled
2 Trials studying Autism Spectrum Disorder
79 Patients Enrolled for Autism Spectrum Disorder

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025